Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7562-7569

  Peer, Dan ^a   Dekel, Yaron ^a   Melikhov, Dina ^a   Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DOXORUBICIN; FLUOXETINE; MITOMYCIN C; PACLITAXEL; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SAFETY; DRUG SOLUBILITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLUOXETINE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MITOMYCIN; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; TISSUE DISTRIBUTION; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 5644269048     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-4046     Document Type: Article

References (39)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002;2:48-58.
2. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12:450-8.
3. Sonneveld P, Wiemer E. Inhibitors of multidrug resistance. Curr Opin Oncol 1997; 9:543-8.
4. Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997;77:545-90.
5. Barrows LR. Antineoplastic and Immunoactive Drugs in: Affonso RG, editor. Remington:The Science and Practice of Pharmacy. Easton PA: Mack Publishing Co; 1995. p. 1236-62.
6. Izquierdo MA. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996;19:191-7.
7. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 2002;26:143-54.
8. Tsuruo T, Lida H, Nojri M, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
9. Yung BY, Chang FJ, Bor AM. Modulation of the reversibility of Actinomycin D cytotoxicity in HeLa cells by verapamil. Cancer Lett 1991;60:221-7.
10. Foxwell BMJ, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein. Molecul Pharmcol 1989;36: 543-6.
11. Twentyman PR, Fox NE, White DJ. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987;56:55-7.
12. Naito M, Yusa K, Tsuruo T. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein. Biochem Biophys Res Comm 1989;158: 1066-71.
13. Yang CP, DePinoho SG, Greenberger LM, Arceci JR, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989;264:782-8.
14. Ganapath R, Grabowski D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res 1983;43: 3696-9.
15. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997;8: 125-40.
16. Atadja P, Watanabe T, Xu H, Cohen D. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev 1998;17:163-8.
17. Dale IL, Tuffley W, Callaghan R, et al. Reversal of P-glycoprotein- mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 1998; 8:885-92.
18. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;40:Suppl S13-19.
19. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 1998;6:2964-76.
20. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-602.
21. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyl dibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-79.
22. Starling JJ, Shepard RL, Cao J, et al. Pharmacological characterization of LY335979: a potent yclopropyl dibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 1997;37:335-47.
23. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000;60:2964-72.
24. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093 - a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 2002;27:119-26.
25. Zhang C, Sarshar S, Moran EJ, et al. 2,4,5- Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2 Bioorg Med Chem Lett 2000;10:2603-5.
26. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749-58.
27. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6: 4186-91.
28. Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res 2002;8:582-8.
29. Baggetto LG, Dong M, Bernaud J, Espinosa L, Rigal D, Bonvallet R, Marthinet E. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin Biochem Pharmacol 1998;56:1219-28.
30. 99mTc-Sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003;9: 650-6.
31. Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86:302-10.
32. Toppmeyer D, Seidman AD, Pollak M, et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002;8:670-8.
33. Cookson J, Duffett R. Fluoxetine: therapeutic and undesirable effects. Hosp Med 1998;59:622-6.
34. Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Inter J Cancer 2004;108:780-9.
35. Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 2002;38:418-26.
36. Yoon SS, Fidler IJ, Beltran PJ, Bucana CD, Wang YF, Fan D. Intratumoral heterogeneity for and epigenetic modulation of mdr-1 expression in murine melanoma. Melanoma Res 1997;7:275-87.
37. Bruno NA, Carver LA, Slate DL. Isolation and characterization of doxorubicin-resistant Lewis lung carcinoma variants. Cancer Commun 1990;2:151-8.
38. Michowitz M, Dayan-Avidan G, Bar-Shira-Maymon B, Donin N, Leibovici J. Drug resistance and its counteraction by cyclosporin A in function of metastatic potential in the Lewis lung carcinoma system. Cell Mol Biol 1994;40:551-60.
39. Naito M, Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PCS 833. Cancer Chemother Pharmacol 1997;40:Suppl S20-4.